Primary prophylaxis of variceal bleeding

Gastrointestinal Endoscopy

Volumn 58, Issue 4, 2003, Pages 558-567

  Thuluvath, Paul J ^a,b   Krishnan, Aruna ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL; NITRATE; PLACEBO; PROPRANOLOL; SPIRONOLACTONE;

BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG UTILIZATION; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FATIGUE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPOTENSION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK FACTOR; SCORING SYSTEM; SEPSIS; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTE COUNT; VEIN DIAMETER; VEIN LIGATION;

ADRENERGIC BETA-ANTAGONISTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOSORBIDE DINITRATE; LIGATION; MARKOV CHAINS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RISK FACTORS; SCLEROTHERAPY; VASODILATOR AGENTS;

EID: 0141483228     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0016-5107(03)01971-0     Document Type: Review

References (59)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. 1. Portal hypertension. J Hepatol 2000;32(1 Suppl):141-56.
2. Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989;96:1552-9.
3. Merigan TC, Plotkin GR, Davidson CS. Effect of intravenously administered posterior pituitary extract on hemorrhage from bleeding esophageal varices. N Engl J Med 1962;266: 134-5.
4. Conn HO, Ramsby GR, Storer EH, Mutchnick MG, Joshi PH, Phillips MM, et al. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective controlled clinical trial. Gastroenterology 1975;68:211-21.
5. Fogel RM, Knauer MC, Andres LL, Mahal AS, Stein D, Kemeney JM, et al. Continuous intravenous vasopressin in active upper gastrointestinal bleeding. A placebo controlled trial. Ann Intern Med 1982;96:565-9.
6. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
7. Dy SM, Cromwell DM, Thuluvath PJ, Bass EB. Hospital experience and outcomes for esophageal variceal bleeding. Int J Qual Health Care 2003;15:139-46.
8. Plevris JN, Elliot R, Mills PR, Hislop WS, Davies JM, Bouchier IA, Hayes PC. Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. Aliment Pharmacol Ther 1994;8:63-70.
9. Schepis F, Camma C, Niceforo D, Magnano A, Pallio S, Cinquegrani M, et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology 2001;33:333-8.
10. Zaman A, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med 2001;161:2564-70.
11. Chalasani N, Imperiale TF, Ismail A, Sood G, Carey M, Wilcox CM, et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol 1999;94:3285-91.
12. Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 2002; 122:1620-30.
13. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multi-center study. N Engl J Med 1988;319:983-9.
14. Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981;27:213-8.
15. Sarin SK, Sundaram KR, Ahuja RK. Predictors of variceal bleeding: an analysis of clinical, endoscopic and hemodynamic variables, with special reference to intravariceal pressure. Gut 1989;30:1757-64.
16. Bendsten F, Skovgaard LT, Sorensen TI, Matzen P. Agreement among multiple observers on endoscopic diagnosis of esophageal varices before bleeding. Hepatology 1990;11:341-7.
17. Idezuki Y. General rules for recording endoscopic findings of esophagogastric varices (1991). Japanese Society for Portal Hypertension. World J Surg 1995;19:420-2.
18. Dagradi AE. The natural history of esophageal varices in patients with alcoholic liver cirrhosis. An endoscopic and clinical study. Am J Gastroenterol 1972;57:520-40.
19. Viallet A, Marleau D, Huet M, Martin F, Farley A, Villeneuve JP, Lavoie P. Hemodynamic evaluation of patients with intrahepatic portal hypertension: relationship between bleeding varices and portohepatic gradient. Gastroenterology 1975;69: 1297-1300.
20. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tso G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of variceal hemorrhage. Gastroenterology 1990;99:1401-7.
21. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
22. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701-9.
23. Akanuma M, Yoshida H, Okamoto M, Ogura K, Maeda S, Hata Y, et al. Risk factors for esophageal variceal bleeding in patients with hepatocellular carcinoma. Hepatogastroenterology 2002;49:1039-44.
24. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22: 332-54.
25. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention bleeding: A meta-analysis. Hepatology 1999;30:612-22.
26. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in alcoholic liver disease: a randomized, single-blind, multicenter clinical trial. N Engl J Med 1991;324:1779-84.
27. Van Ruiswyk J, Byrd JC. Efficacy of prophylactic sclerotherapy for prevention of a first variceal hemorrhage. Gastroenterology 1992;102:587-97.
28. Pagliaro L, D'Amico G, Sorensen TI, Lebrec D, Burroughs AK, Morabito A, et al. Prevention of first bleeding in cirrhosis: a meta-analysis of randomized trials of non-surgical treatment. Ann Intern Med 1992;117:59-70.
29. Lebrec D, Corbic M, Nouel O, Benhamou P. Propranolol: a medical treatment for portal hypertension. Lancet 1980;2:180-2.
30. Pascal JP, Cales P, Multicenter Study Group. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varies. N Engl J Med 1987;317:856-61.
31. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic antagonists in the prevention of first gastrointestinal bleeding in patients with cirrhosis and oesophageal varices. Analysis of data and prognostic factors in 589 patients from four randomized clinical trial. N Engl J Med 1991;324:1532-8.
32. Hayes PC, Davis JM, Lewis JA, Bouchier IAD. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990;336:153-6.
33. Abraczinskas DR, Ookubo R, Grace ND, Groszmann RJ, Bosch J, Garcia-Tsao G, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology 2001;34:1096-102.
34. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta L. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;32:930-4.
35. De BK, Sen S, Biswas PK, Sengupta D, Biswas J, Santra A, et al. Propranolol in primary and secondary prophylaxis of variceal bleeding among cirrhotics in India: a hemodynamic evaluation. Am J Gastroenterol 2002;95:1862-4.
36. Hicken BL, Sharara AI, Abrams GA, Eloubeidi M, Fallon MB, Arguedas MR. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Aliment Pharmacol Ther 2003;17:145-53.
37. Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 2000;118:1261-5.
38. Garcia-Pagan JC, Villanueva C, Vila MC, Albillos A, Genesca J, Ruiz-Del-Arbol L, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001;121:908-14.
39. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997;113:1632-9.
40. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995;123:280-7.
41. Sarin SK, Gupta RK, Jain AK, Sundaram KR. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol 1996;8:337-42.
42. Lay CS, Tsai YT, Teg CY, Shyu WS, Guo WS, Wu KL, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997;25:1346-50.
43. Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI, Chiang HT. Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. J Hepatol 1999;31:451-6.
44. Svoboda P, Kantorova I, Ochmann J, Kozumplik L, Marsova J. A prospective randomized controlled trial of sclerotherapy vs. ligation in the prophylactic treatment of high-risk esophageal varices. Surg Endosc 1999;13:580-4.
45. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-93.
46. Burroughs AK, Patch D. Primary prevention of bleeding from esophageal varices. N Engl J Med 1999;340:1033-5.
47. Lui HF, Stanley AJ, Forrest EH, Jalan R, Hislop WS, Mills PR, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735-44.
48. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001;33:802-7.
49. Avgerinos A, Armonis A, Manolakopoulos S, Rekoumis G, Argirakis G, Viazis N, et al. Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: a prospective multicenter randomized trial. Gastrointest Endosc 2000;51:652-8.
50. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, et al. Randomized trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996;348:1677-81.
51. Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;31: 324-9.
52. Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. Ann Intern Med 1991;114:869-73.
53. Abecasis R, Kravetz D, Fassio E, Ameigeiras B, Garcia D, Isla R, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003;37:359-65.
54. Arguedas MR, McGuire BM, Fallon MB, Abrams GA. The use of screening and preventive therapies for gastroesophageal varices in patients referred for evaluation of orthotopic liver transplantation. Am J Gastroenterol 2001;96:833-7.
55. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology 1997;112:473-82.
56. Spiegel BM, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology 2003;37:366-77.
57. Saab S, DeRosa V, Nieto J, Durazo F, Han S, Roth B. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol 2003;98:763-70.
58. Arguedas MR, Heudebert GR, Eloubeidi MA, Abrams GA, Fallon MB. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol 2002;97:2441-52.
59. Andreani T, Poupon RE, Balkau BJ, Trinchet JC, Grange JD, Peigney N, et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology 1990;12:1413-9.